Medivir: The Nomination Committee’s Proposal, with Reference to the Upcoming 2014 Annual General Meeting, for a New Board of Directors

Regulatory News:

Medivir AB (STO:MVIR-B) announced today the Nomination Committee’s proposal, with reference to the upcoming 2014 Annual General Meeting, for a new Board of Directors. The 2013-2014 Nomination Committee comprises representatives of the three largest shareholders in the company at the end of the third quarter of 2013 who have accepted a seat on the Nomination Committee, together with the Chairman of the Board. The composition of the 2013-2014 Nomination Committee was as follows:

• Anders Algotsson, Chairman of the Nomination Committee, representing AFA Försäkring
• Annelie Enquist, representing Skandia Fonder
• Göran Pettersson, Chairman of the Board of Medivir AB
• Bo Öberg, representing the class A shareholders

The Nomination Committee has agreed to propose, with reference to the upcoming 2014 Annual General Meeting, that a new Board of Directors be appointed by means of the re-election of the Board’s existing Members, namely Björn C Andersson, Anna Malm Bernsten, Anders Hallberg and Birgitta Stymne Göransson, and the new election of three Members, namely Anders Ekblom, Niklas Prager and Bertil Samuelsson. Birgitta Stymne Göransson is proposed to be elected Chairman of the Board.

Rolf A Classon, Ingemar Kihlström, Göran Pettersson and Bo Öberg have declined re-election.

Anders Ekblom, born 1954, is a physician (specialising in anaesthesia and intensive care), dentist, Doctor of Medicine, and an Associate Professor in physiology at the Karolinska Institute. Anders has previously worked at AstraZeneca for 19 years in a number of positions, including Executive Vice President Global Medicines Development, and CEO of AstraZeneca AB in Sweden. He has extensive experience of pharmaceutical development work in numerous therapeutic areas, including inflammation, cardiovascular disease, oncology, the nervous system and infectious diseases. He is currently a Member of the Boards of the Karolinska University Hospital and SwedenBio, and is a senior advisor for Phase4 Partners, UK.

Niklas Prager, born 1970, holds a Master of Business Administration degree from the Stockholm School of Economics and the University of Michigan. Niklas has many years’ experience of senior executive positions in trade and industry, both as CEO and as Board Member, and has extensive experience of company management, sales and marketing. He has worked in both Sweden and the USA for Merck & Co. Inc. and has been the CEO of Pfizer AB, Qbtech AB and Envirotainer AB. Niklas is currently the Chairman of the Board of Qbtech AB and a Member of the Board of eGain Group AB. He is also a former Chairman of the Boards of BioPhausia AB, Envirotainer AB and Michael Berglund Search Group AB.

Bertil Samuelsson, born 1950, gained a Ph.D. in 1980 as a post-doctoral research fellow under Professor E.J. Corey at Harvard University in the USA, and was an Associate Professor and Visiting Professor at Stockholm University in 1985. Bertil held the position of Chief Scientific Officer, and subsequently of Chief Scientific Officer of Research & Development at Medivir between 1999 and 2010. He has served, from 2011 to the present day, as the Chief Scientific Advisor for Medivir and is fully familiar with the company’s operations and its projects. He was previously, from 1987, Head of Medicinal Chemistry at AstraZeneca, Mölndal. He has held seats on the Boards of ACTAR, NovaSaid and Toscana Life Sciences Foundation and the Swedish Pharmaceutical Society, and has acted as an advisor to AstraZeneca R&D Bangalore. He has published over 170 peer-reviewed articles, including a large number in the area of infectious diseases, and is listed as a co-inventor on approximately 40 patent applications, a large number of which have been granted.

This information was brought to you by Cision http://news.cision.com